Search
Elexacaftor
go.drugbank.com/drugs/DB15444ApprovedInvestigational[L9395] Elexacaftor is considered a next-generation CFTR corrector as it possesses both a different structure and mechanism as compared to first generation correctors like tezacaftor. … [A187361] It received FDA approval in October 2019 in combination with [tezacaftor] and [ivacaftor] as the combination product Trikafta<sup>TM</sup>.
Lisocabtagene maraleucel
go.drugbank.com/drugs/DB16582ApprovedInvestigational[A228493] Lisocabtagene maraleucel was granted FDA approval on 5 February 2021 [L31583] and EC approval on 5 April 2022.[L42210] It was later granted Health Canada approval on 6 May 2022. … [L31588] CAR T-cell therapy has changed the treatment of B-cell lymphomas, significantly increasing survival rates over standard therapy.
Palovarotene
go.drugbank.com/drugs/DB05467ApprovedIt first garnered interest as a potential treatment for emphysema but was eventually recognized as a potential novel therapy for patients with FOP. … [L39990,L40020] It has been granted rare pediatric disease and breakthrough therapy designations from the US FDA, although a previously submitted NDA was withdrawn in August 2021 pending the resubmission
Ceftazidime
go.drugbank.com/drugs/DB00438ApprovedInvestigationalBacteria possess a cell wall comprising a glycopeptide polymer commonly known as peptidoglycan, which is synthesized and remodelled through the action of a family of enzymes known as "penicillin-binding … [A232920, A232925, A232930] Ceftazidime is a third-generation cephalosporin with broad-spectrum antibacterial activity, including against some treatment-resistant bacteria such as _Pseudomonas aeruginosa
Products: CEF-4 500MG INJECTION, Fortaz Inj 500mg/vialNitrous acid
go.drugbank.com/drugs/DB09112ApprovedInvestigationalNitrous acid (as sodium nitrite) is used as part of an intravenous mixture with sodium thiosulfate to treat cyanide poisoning.
Remibrutinib
go.drugbank.com/drugs/DB16852ApprovedInvestigational[A274501, L54101] Remibrutinib has also been investigated in other inflammatory conditions,[A274511] such as autoimmune encephalomyelitis [A274501] and Sjögren's syndrome.[A274521] … The FDA approved remibrutinib on September 30, 2025 as the only oral, targeted treatment for chronic spontaneous urticaria.
Remimazolam
go.drugbank.com/drugs/DB12404ApprovedInvestigational[A214852,A214857] Remimazolam was the first "soft" benzodiazepine analog to be developed[A214862] and was approved for use by the FDA in July 2020 under the brand name Byfavo.[L14722] … susceptible to rapid biotransformation and elimination as inactive metabolites.
Ozanimod
go.drugbank.com/drugs/DB12612ApprovedInvestigationalIt was developed by Celgene (now acquired by Bristol-Myers Squibb) [L11025] and was approved by the FDA on March 26, 2020. … [L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020.
Halazepam
go.drugbank.com/drugs/DB00801ApprovedIllicitWithdrawn[A1212, A178114] It has been shown to be less toxic than chlordiazepoxide or diazepam. … [A1212] This drug is no longer marketed in the United States, and was withdrawn by _Schering_, its manufacturer, in 2009.[L6226, L6229]
Tea tree oil
go.drugbank.com/drugs/DB11218ApprovedNutraceuticalIt may be referred to as _Melaleuca alternifolia_ oil. … It has been a popular ingredient in a variety of household and cosmetic products due to its antiseptic, anti-inflammatory, broad-spectrum antimicrobial and antioxidant properties [A32438].